Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

35.72
+0.22000.62%
Post-market: 35.50-0.2200-0.62%19:30 EDT
Volume:4.37M
Turnover:155.72M
Market Cap:25.80B
PE:-76
High:36.00
Open:35.61
Low:35.19
Close:35.50
52wk High:42.50
52wk Low:15.25
Shares:722.41M
Float Shares:581.00M
Volume Ratio:0.76
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:6.10
PE(LYR):-66.15

Loading ...

Bellevue Flags US Healthcare Innovation as Driving Fresh Investment Opportunities

Reuters
·
Sep 14

Roivant Sciences Director Meghan FitzGerald Disposes of USD 798,000 in Common Shares

Reuters
·
Sep 11

Roivant Sciences Price Target Raised to $46.00/Share from $42.00 by Guggenheim

Dow Jones
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Top Midday Gainers

MT Newswires Live
·
Sep 09

Roivant Sciences price target raised to $47 from $41 at H.C. Wainwright

TIPRANKS
·
Sep 09

Roivant Sciences rises 17.6%

TIPRANKS
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Movement Alert|Roivant Sciences Ltd. Rises 14.2% in Regular Trading, Core Pipeline Mosliciguat Phase 2 Study Meets Primary Endpoint

Market Focus
·
Sep 08

Update: US Equity Futures Mostly Lower as Traders Assess Rising Oil, Canadian Retaliatory Tariffs

MT Newswires Live
·
Sep 08

Top Premarket Gainers

MT Newswires Live
·
Sep 08

Roivant Sciences Shares Rise on Positive Mid-Stage Trial Results

Dow Jones
·
Sep 08

Roivant Sciences Jumps After Lung Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 08

Shares of Roivant Sciences up 21.1% Premarket After Experimental Lung Disease Drug Meets Main Goal in Mid-Stage Study

THOMSON REUTERS
·
Sep 08

Movement Alert|Roivant Sciences Ltd. Rises 28.66% in Pre-Market Trading, Core Pipeline Mosliciguat Achieves Positive Clinical Data in PH-ILD Study

Market Focus
·
Sep 08

Roivant Says Phase 2 PHocus Trial Shows Mosliciguat Cuts Pulmonary Vascular Resistance 56.3% in PH-ILD

Reuters
·
Sep 08

Roivant Sciences Ltd - Phocus Met Its Primary Endpoint

THOMSON REUTERS
·
Sep 08

Roivant Announces Positive Results from Phocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (Ph-Ild) and Unveils Ongoing Phase 3 Phrontier Study

THOMSON REUTERS
·
Sep 08

Roivant Sciences - Mosliciguat Shows Lower Cough Incidence than Placebo in Phocus Study

THOMSON REUTERS
·
Sep 08

Roivant Sciences Ltd - Mosliciguat Observed to be Well Tolerated with a Favorable Safety Profile

THOMSON REUTERS
·
Sep 08